ArtemiX Biotech

🔵 AV Fistula Failure: Are We Too Late, Too Often? In hemodialysis, arteriovenous (AV) fistulas remain the gold standard for vascular access. And yet, up to 60% fail to mature properly, often long before they can be used. Why? The causes are well known: early thrombosis, poor vessel remodeling, venous stenosis, and persistent inflammation. But the consequences are still too frequent — delayed dialysis, catheter overuse, repeated interventions, and most importantly, patient risk. 🔶 The real problem isn’t just biological — it’s strategic. We continue to respond to complications instead of preventing them. Each AV access failure leads to costly hospitalizations, capital loss of usable vessels, and emotional burden for patients and caregivers. An average thrombectomy can cost $10,000+, not counting downtime and long-term impact on vascular health. So why haven’t we changed our approach? 🔍 Because prevention is still a blind spot. ➡️ We lack predictive tools ➡️ We lack validated preventive treatments ➡️ And we lack coordinated care between nephrologists, vascular surgeons, and dialysis teams Yet the need for a shift is clear. 🟢 A proactive strategy can improve AV fistula maturation, reduce complications, and lighten the load on the healthcare system. 🧬 And now, biotech innovation is rising to meet this challenge — bringing new preventive solutions that target failure before it starts. This is more than a treatment question — it’s a paradigm shift. 🗣️ If you're a nephrologist, vascular surgeon, or dialysis center interested in rethinking vascular access care — let’s connect. Together, we can move from crisis management to prevention. #Hemodialysis #VascularAccess #AVFistula #Nephrology #VascularSurgery #DialysisInnovation #CKD #Biotech #PreventiveMedicine #RenalCare